A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids	Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy	Active, not recruiting	Phase 3	2026-08-21		NCT05653219

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Novartis Pharmaceuticals	432

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Boston Medical Center	Boston	United States	200
Hematology Oncology Association of Rockland	Nyack	United States	2
Michigan Center of Medical Research	Farmington Hills	United States	9
Montefiore Medical Center	The Bronx	United States	79
NorthShore University Health System	Evanston	United States	24
St Vincent Frontier Cancer Center	Billings	United States	4
UMASS Memorial Medical Center	Worcester	United States	1
University of Colorado Anschutz	Aurora	United States	30
Yuma Regional Medical Center	Yuma	United States	2